Injection moulding : a novel approach to the manufacture of homogenous immediate release solid oral dosage forms by Wood, Sarahjane et al.
Strathprints Institutional Repository
Wood, Sarahjane and Halbert, Gavin and Florence, Alastair (2016) 
Injection moulding : a novel approach to the manufacture of 
homogenous immediate release solid oral dosage forms. In: 7th APS 
International PharmSci Conference, 2016-09-05 - 2016-09-07. , 
This version is available at http://strathprints.strath.ac.uk/57644/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
Sarahjane Wood1, Gavin W. Halbert1,2 & Alastair. Florence1
1The EPSRC Doctoral Training Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, The University of Strathclyde, Glasgow, UK.
2The Cancer Research UK Formulation Unit, the Strathclyde Institute of Pharmacy and Biomedical Sciences, the University of Strathclyde, Glasgow, UK.
Injection Moulding: A novel approach to the 
manufacture of homogenous immediate release 
solid oral dosage forms 
Injection Moulding:
 Injection of molten material under 
pressure
 Product cools in mould then removed
 Commonly used for
 Packaging
 Biomedical devices
 Create solid oral  dosage forms
 Makes use of polymers
 Scalable
 Dosage shape dependent on mould-
designable
 No solvents needed
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Dissolution studies:
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Low API 
conc.
175 70 500 bar
Medium API 
conc.
175 70 500 bar
High API
conc.
175 70 500 bar
IM conditions:
Aim: to produce a solid oral dosage form that is immediate release using Injection Moulding and Hot Melt Extrusion
Solid State Analysis: Conclusion:
 Release profiles not immediate- almost 100% of drug should be released within 1 hour 
however in this case a fraction of that is released and full dissolution occurs between 4 and 
17 hours
 Drug release after the first few hours is hindered due to the slow erosion properties of the 
polymer 
 Further optimisation of formulation and process is required as well as more representative 
analysis
Further Work:
 Full investigation into polymer and disintegrant compatibility and effect of disintegrant on 
polymer break up
 Altering formulation to contain disintegrants allowing for immediate release of drug
 Analysis of extrudates to determine exact API release
 New mould design to control API distribution
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Images of IM dosage units, from left to 
right: low, medium & high concentration 
of API
 The dissolution profile show that an immediate release of the API is not achieved. This is most likely due 
to the polymer hindering drug release as the main mechanism of achieved release of drug is through 
polymer erosion. 
 Most drug release occurs during the first few hours of dissolution when the concentration of drug is at its 
highest. It then slows down as the effects of the slowly eroding polymer take over.
 Drug release between samples of the same formulation are very similar showing that both methods of 
production are reproducible. However more analysis of the extrudates used is required to determine 
their true concentration to give a more accurate HME-IM drug release
Material extruded using same temperature profiles to 
form a  strand which was then pelletized  
DSC
 The melting point for the drug is not present in the DSC traces (not shown) 
for low and medium API concentration formulations which suggests the 
drug is present in the amorphous form. This is to be expected as the drug 
has been melted and the polymer is preventing recrystallisation. 
 The high concentration API dosage units show a recrystallisation event and 
in storage the units turned white. This suggests that the polymer is 
saturated and can no longer prevent the crystallisation of API.
XRD
 X-ray diffraction confirmed that the API in the low and medium 
concentration solid oral dosage forms is amorphous due to lack of distinct 
peaks corresponding to the drug (diffractograms not shown).
 The data also confirmed that as the dosage forms containing the high 
concentration of API turned white recrystallisation was occurring.
High concentration 
dosage forms turning 
white after storage
Dissolution profiles above show the drug release for dosage forms produced from powder mixtures (PM-IM) and from the extrudates formed from these powder mixtures via Hot Melt Extrusion (HME-IM)
